12月31日，华康洁净盘中下跌2.02%，截至13:58，报36.80元/股，成交1.52亿元，换手率5.60%，总市值 39.66亿元。 分红方面，华康洁净A股上市后累计派现4002.14万元。近三年，累计派现2946.14万元。 机构持仓方面，截止2025年9月30日，华康洁净十大流通股东中，富国优化增强债券A/B（100035）位 居第六大流通股东，持股180.00万股，为新进股东。富国久利稳健配置混合型A（003877）位居第九大 流通股东，持股49.78万股，为新进股东。招商量化精选股票发起式A（001917）位居第十大流通股东， 持股47.00万股，为新进股东。安信医药健康股票A（010709）、诺安多策略混合A（320016）退出十大 流通股东之列。 责任编辑：小浪快报 资料显示，武汉华康世纪洁净科技股份有限公司位于湖北省武汉市东湖新技术开发区高新大道718号3 栋，成立日期2008年11月12日，上市日期2022年1月28日，公司主营业务涉及医疗净化系统研发、设 计、实施和运维,相关医疗设备和医疗耗材的销售。主营业务收入构成为：净化系统集成85.24%，医疗 耗材销售8.53%，医疗设备销售3 ...

Core Viewpoint - The stock of Bio Co., Ltd. has experienced significant fluctuations, with a year-to-date increase of 120.79% but a recent decline of 10.77% over the past five trading days, indicating volatility in investor sentiment and market performance [1]. Company Performance - As of September 30, 2025, Bio Co., Ltd. reported a revenue of 1.042 billion yuan, reflecting a year-on-year growth of 7.38%, while the net profit attributable to shareholders decreased by 4.85% to 161 million yuan [2]. - The company has a cumulative cash distribution of 2.219 billion yuan since its A-share listing, with 189 million yuan distributed over the past three years [3]. Shareholder Information - The number of shareholders for Bio Co., Ltd. decreased by 10.70% to 49,000, while the average number of circulating shares per person increased by 11.12% to 22,673 shares [2]. - Notable institutional shareholders include Guotai CSI Livestock Breeding ETF, which increased its holdings by 9.09 million shares, and Hong Kong Central Clearing Limited, which added 1.094 million shares [3]. Market Activity - The stock price of Bio Co., Ltd. was reported at 15.08 yuan per share, with a market capitalization of 16.765 billion yuan. The trading volume was 83.7786 million yuan, with a turnover rate of 0.50% [1]. - The stock has appeared on the "Dragon and Tiger List" four times this year, with the most recent instance on December 24, where it recorded a net buy of -63.219 million yuan [1].

Core Viewpoint - Huakang Clean has experienced significant stock price fluctuations, with a year-to-date increase of 90.32% but a recent decline of 13.23% over the past five trading days [1] Group 1: Stock Performance - As of December 30, Huakang Clean's stock price is 38.37 yuan per share, with a market capitalization of 4.135 billion yuan [1] - The stock has seen a trading volume of 50.0591 million yuan and a turnover rate of 1.78% [1] - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent appearance on July 31 [1] Group 2: Financial Performance - For the period from January to September 2025, Huakang Clean achieved a revenue of 1.431 billion yuan, representing a year-on-year growth of 32.59% [2] - The net profit attributable to shareholders for the same period was 61.1567 million yuan, showing a substantial increase of 211.46% year-on-year [2] Group 3: Business Overview - Huakang Clean, established on November 12, 2008, specializes in the research, design, implementation, and operation of medical purification systems, along with the sale of related medical equipment and consumables [1] - The revenue composition of the company includes 85.24% from purification system integration, 8.53% from medical consumables sales, 3.74% from medical equipment sales, 1.88% from operation and maintenance services, and 0.61% from other sources [1] Group 4: Shareholder Information - As of December 19, the number of Huakang Clean's shareholders increased to 10,700, a rise of 3.08% from the previous period [2] - The average number of tradable shares per shareholder is 6,802, which has decreased by 2.99% [2] - New institutional shareholders include Fuguo Optimized Enhanced Bond A/B and Fuguo Jiuli Steady Allocation Mixed A, among others [3]

Group 1 - The core viewpoint of the news is that Chuangyuan Technology's stock has experienced significant fluctuations, with a recent drop of 8.72% on December 29, 2023, and a total market value of 7.509 billion yuan [1] - Chuangyuan Technology's stock price has increased by 56.73% year-to-date, with notable gains of 23.62% in the last five trading days, 43.69% in the last 20 days, and 33.42% in the last 60 days [2] - The company has appeared on the stock market's "龙虎榜" (top trading list) twice this year, with the most recent appearance on December 26 [2] Group 2 - Chuangyuan Technology's main business segments include clean equipment and engineering (47.30% of revenue), high-voltage porcelain insulators for power transmission and transformation (24.65%), precision bearings (17.18%), grinding tools and materials (5.45%), surveying instruments (3.19%), and trade and services (2.23%) [2] - As of September 30, 2023, the number of shareholders for Chuangyuan Technology was 29,700, an increase of 15.95% from the previous period, with an average of 16,268 circulating shares per person, up by 3.50% [2] - For the first nine months of 2023, Chuangyuan Technology reported operating revenue of 3.123 billion yuan, a year-on-year decrease of 6.96%, while net profit attributable to shareholders increased by 3.25% to 219 million yuan [2] Group 3 - Chuangyuan Technology has distributed a total of 523 million yuan in dividends since its A-share listing, with cumulative distributions of 96.9523 million yuan over the past three years [3]

《生物安全法案》复盘 --如何看待地缘政治对中国CXO企业的影响？ 行业研究 · 行业专题 医药生物 · 医疗研发外包 投资评级：优于大市（维持评级） 0755-81982723 pengsiyu@guosen.com.cn S0980521060003 证券分析师：陈曦炳 0755-81982939 chenxibing@guosen.com.cn S0980521120001 证券分析师：彭思宇 证券分析师：凌珑 021-60375401 linglong@guosen.com.cn S0980525070003 请务必阅读正文之后的免责声明及其项下所有内容 1 报告摘要 证券研究报告 | 2025年12月28日 n 靴子落地，美国《2026财年国防授权法案》夹带《生物安全法案》生效。 请务必阅读正文之后的免责声明及其项下所有内容 2 ü 《2026财年国防授权法案》夹带《生物安全法案》（主要指第851节《禁止与特定生物技术公司签订合同》）落地，标志着美国已将生物安全正式纳入国家防务与 安全战略框架统筹考量，同时彰显其在生物技术供应链自主可控的明确政策转向，本质是中美的科技竞争与产业安全博弈在生物领域的延 ...

Core Viewpoint - The news highlights the performance and strategic initiatives of Lanzhou Zhuangyuan Pasture Co., Ltd., focusing on its market position in the dairy industry and its efforts in brand promotion and rural revitalization. Company Overview - Lanzhou Zhuangyuan Pasture Co., Ltd. is primarily engaged in the production, processing, and sales of dairy products and milk beverages, with a product range that includes pasteurized milk, sterilized milk, fermented milk, and various liquid dairy products under brands such as "Zhuangyuan Pasture," "Shenghu," and "Dongfang Duoxian Zhuangyuan" [2][3][9]. Financial Performance - For the period from January to September 2025, the company reported a revenue of 629 million yuan, representing a year-on-year decrease of 3.10%. The net profit attributable to the parent company was -48.44 million yuan, showing a year-on-year increase of 59.08% [9]. Market Position - The company has established itself as a leading dairy product enterprise in Gansu and Qinghai, with a market share of approximately 20% [3]. Strategic Initiatives - The company has implemented a series of integrated marketing strategies, including leveraging tourism routes to promote new products and enhancing online sales through platforms like Douyin and Xiaohongshu [2][4]. - It has also focused on rural revitalization by engaging with local cooperatives and farmers, promoting income growth through logistics agreements and order-based procurement models [4]. Ownership and Governance - The company is a state-owned enterprise, ultimately controlled by the Gansu Provincial Government's State-owned Assets Supervision and Administration Commission [4]. Shareholder Information - As of September 30, 2025, the company had 18,100 shareholders, a decrease of 12.97% from the previous period, with an average of 9,466 circulating shares per person, an increase of 14.91% [9][10].

12月25日，庄园牧场盘中下跌2.05%，截至10:05，报11.95元/股，成交1.83亿元，换手率8.84%，总市值 23.37亿元。 截至9月30日，庄园牧场股东户数1.81万，较上期减少12.97%；人均流通股9466股，较上期增加 14.91%。2025年1月-9月，庄园牧场实现营业收入6.29亿元，同比减少3.10%；归母净利润-4844.08万 元，同比增长59.08%。 分红方面，庄园牧场A股上市后累计派现6469.32万元。近三年，累计派现1219.53万元。 机构持仓方面，截止2025年9月30日，庄园牧场十大流通股东中，诺安多策略混合A（320016）位居第 六大流通股东，持股144.98万股，相比上期增加35.02万股。中信保诚多策略混合(LOF)A（165531）位 居第八大流通股东，持股95.24万股，为新进股东。 责任编辑：小浪快报 今年以来庄园牧场已经13次登上龙虎榜，最近一次登上龙虎榜为12月24日，当日龙虎榜净买入-442.59 万元；买入总计3923.04万元 ，占总成交额比6.49%；卖出总计4365.63万元 ，占总成交额比7.22%。 资料显示，兰州庄园牧场股份有限 ...

Core Viewpoint - The company, Lanzhou Zhuangyuan Pasture Co., Ltd., is facing challenges in the traditional dairy industry but is exploring new opportunities in the pet food sector with the launch of its brand "Safiyy" at the Asia Pet Expo [3]. Company Overview - Lanzhou Zhuangyuan Pasture Co., Ltd. primarily engages in the production, processing, and sales of dairy products and dairy beverages, as well as dairy cattle farming. Its product range includes pasteurized milk, sterilized milk, modified milk, fermented milk, and various liquid dairy products under the brands "Zhuangyuan Pasture," "Shenghu," and "Dongfang Duoxian Zhuangyuan" [2][8]. - The company was established on April 25, 2000, and went public on October 31, 2017. It is located in Lanzhou, Gansu Province [8]. Financial Performance - For the period from January to September 2025, the company reported a revenue of 629 million yuan, a year-on-year decrease of 3.10%. The net profit attributable to the parent company was -48.44 million yuan, showing a year-on-year increase of 59.08% [9]. - The company's main business revenue composition includes sterilized milk (37.04%), fermented milk (24.37%), modified milk (22.21%), pasteurized milk (8.20%), fresh milk (4.60%), and other products (2.77%) [9]. Market Position and Strategy - The company has a market share of 20% in the dairy product sector in Gansu and Qinghai, positioning itself as a leading enterprise in the region [3]. - The company has implemented a series of integrated marketing strategies, including leveraging tourism routes and online platforms to promote new products and enhance brand visibility [2]. Ownership and Control - The company is a state-owned enterprise, ultimately controlled by the Gansu Provincial Government's State-owned Assets Supervision and Administration Commission [4]. Recent Developments - The company has introduced a new pet food brand "Safiyy," which features a unique "milk beef" as a core ingredient, aiming to tap into the growing pet food market [3].

（原标题：特大走私孕妇血样案涉10万人份样本，血样出境潜藏生物安全风险） 广州海关缉私局破获一起特大走私孕妇血样系列案，该案横跨23个省市，经初步查明，嫌犯团伙累计走 私孕妇血液样本超10万人份。 据央视新闻12月16日报道，嫌犯团伙先在内地招揽有意检测胎儿性别的孕妇，然后将孕妇血样走私到境 外进行化验，每人收费两三千元不等，主要犯罪嫌疑人李某在不到五个月内就非法获利高达700多万 元。 广州海关缉私局在接受央视新闻采访时透露，从2022年起，广州海关缉私部门和海关风控、稽查部门就 对口岸查获的血样违规出口的案件进行了监控，通过互联网摸排，发现有些犯罪团伙通过网络平台，以 胎儿性别鉴定的名义收集孕妇血，走私到境外进行化验。 据智通财经当时报道，这条产业链中的中介和代理遍布内地各大社交网络，只要在小红书上联络一个有 验血服务的医学诊断中心，一天内便会被几个提供该服务的中介陆续关注，微博话题#香港验血测男女# 下，有各种此业务的推广广告，甚至在QQ，也能搜到很多关于香港验血的群。 经济观察网12月18日查询小红书平台发现，目前仍能搜索到少量香港验血查胎儿性别的内容，但大多都 较为隐晦；微博平台上亦有少量账号以"科 ...

美国众议院规则委员会官网等显示，修订后的美国《生物安全法案》已被纳入最新版本2026财年国防授 权法案（NDAA），其中规定将禁止美国联邦机构与"受关注的生物技术公司"签订合同。与去年多个版 本直接点名药明康德等药企不同，今年修订后的法案未具体点名任何企业，但规定后续将由白宫管理和 预算办公室（OMB）在法案通过后一年内，参考美国国防部等相关清单，制定受限企业名单。美众议 院规则委员会将于北京时间12月10日5时开会讨论包含该法案在内的2026年NDAA。 ...